Sponsor:
Imagion Biosystems, Inc.
Code:
NCT07885683
Conditions
HER2-positive Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
The MagSense® HER2 Imaging Agent (MSH2IA)
Brief summary:
Conditions
HER2-positive Breast Cancer
Study ID
NCT07885683
Start date
Nov 30, 2026
Status verified date
Nov, 2026
Completion date
Jul 23, 2029
Anticipated
Primary completion date
Jan 31, 2029
Anticipated
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
70 participants
Anticipated
Allocation
Non randomized
Intervention Model
Sequential
Primary purpose
Diagnostic
Arms
experimental: Phase 1b - MSH2IA Pharmacokinetics
experimental: Phase 2 - MSH2IA Dose and Diagnostic Performance
Interventions
The MagSense® HER2 Imaging Agent (MSH2IA)
Primary outcome measure
Central contacts
Locations
Regis Clinical Research LLC
Recruiting
Miami, Florida, United States, 33126
Contacts
Principal Investigator:
Yilena Rodriguez Marrero, MD
Sponsor
Imagion Biosystems, Inc.
Last update posted
Nov 18, 2026
Last verified
Nov, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Imagion Biosystems, Inc. on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.